;PMID: 7798031
;source_file_816.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..36] = [t:0..36]
;1)sentence:[e:42..201] = [t:42..201]
;2)section:[e:205..226] = [t:205..226]
;3)section:[e:230..363] = [t:230..363]
;4)sentence:[e:367..569] = [t:367..569]
;5)sentence:[e:570..716] = [t:570..716]
;6)sentence:[e:717..787] = [t:717..787]
;7)sentence:[e:788..994] = [t:788..994]
;8)sentence:[e:995..1209] = [t:995..1209]
;9)sentence:[e:1210..1382] = [t:1210..1382]
;10)sentence:[e:1384..1564] = [t:1384..1564]
;11)sentence:[e:1565..1705] = [t:1565..1705]
;12)sentence:[e:1706..2126] = [t:1706..2126]
;13)section:[e:2130..2174] = [t:2130..2174]

;section 0 Span:0..36
;J Endocrinol. 1995 Apr;145(1):59-67.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..12] Endocrinol) (.:[12..13] .)
        (CD:[14..18] 1995) (IN:[19..27] Apr;145-LRB-) (CD:[27..28] 1)
        (-RRB-:[28..29] -RRB-) (CD:[29..32] :59) (TO:[32..33] -)
        (CD:[33..35] 67) (.:[35..36] .)))

;sentence 1 Span:42..201
;Inhibitory and stimulatory effect of oestrogens upon ovarian 17 
;alpha-hydroxylase/C17,20-lyase in immature hypophysectomized rats treated
;with  gonadotrophin.
;[79..89]:substance:"oestrogens"
;[103..124]:cyp450:"17  alpha-hydroxylase"
;[125..137]:cyp450:"C17,20-lyase"
;[187..200]:substance:"gonadotrophin"
(SENT
  (NP-HLN
    (NP
      (NP (JJ:[42..52] Inhibitory)
        (NML-1 (-NONE-:[52..52] *P*)))
      (CC:[53..56] and)
      (NP (JJ:[57..68] stimulatory)
        (NML-1 (NN:[69..75] effect))))
    (PP (IN:[76..78] of)
      (NP (NNS:[79..89] oestrogens)))
    (PP (IN:[90..94] upon)
      (NP (JJ:[95..102] ovarian)
        (NML
          (NML (CD:[103..105] 17) (NN:[107..124] alpha-hydroxylase))
          (SYM:[124..125] /)
          (NML (NN:[125..137] C17,20-lyase)))))
    (PP-LOC (IN:[138..140] in)
      (NP
        (NP (JJ:[141..149] immature) (VBN:[150..167] hypophysectomized)
            (NNS:[168..172] rats))
        (VP (VBN:[173..180] treated)
          (NP (-NONE-:[180..180] *))
          (PP-MNR (IN:[181..185] with)
            (NP (NN:[187..200] gonadotrophin))))))
    (.:[200..201] .)))

;section 2 Span:205..226
;Johnson DC, Crane LH.
(SEC
  (FRAG (NNP:[205..212] Johnson) (NNP:[213..215] DC) (,:[215..216] ,)
        (NNP:[217..222] Crane) (NNP:[223..226] LH.)))

;section 3 Span:230..363
;Department of Gynecology and Obstetrics, RL Smith Research Center, University
;of  Kansas Medical Center, Kansas City 66160-7338, USA.
(SEC
  (FRAG (NNP:[230..240] Department) (IN:[241..243] of)
        (NNP:[244..254] Gynecology) (CC:[255..258] and)
        (NNP:[259..269] Obstetrics) (,:[269..270] ,) (NNP:[271..273] RL)
        (NNP:[274..279] Smith) (NNP:[280..288] Research) (NNP:[289..295] Center)
        (,:[295..296] ,) (NNP:[297..307] University) (IN:[308..310] of)
        (NNP:[312..318] Kansas) (NNP:[319..326] Medical) (NNP:[327..333] Center)
        (,:[333..334] ,) (NNP:[335..341] Kansas) (NNP:[342..346] City)
        (CD:[347..352] 66160) (HYPH:[352..353] -) (CD:[353..357] 7338)
        (,:[357..358] ,) (NNP:[359..362] USA) (.:[362..363] .)))

;sentence 4 Span:367..569
;A study was designed to compare the effects of exogenous and endogenous 
;oestrogens upon the expression of steroid 17 alpha-hydroxylase/C17,20-lyase 
;(CYP17) in the immature hypophysectomized rat ovary.
;[440..450]:substance:"oestrogens"
;[474..502]:cyp450:"steroid 17 alpha-hydroxylase"
;[503..515]:cyp450:"C17,20-lyase"
;[518..523]:cyp450:"CYP17"
(SENT
  (S
    (NP-SBJ-2 (DT:[367..368] A) (NN:[369..374] study))
    (VP (VBD:[375..378] was)
      (VP (VBN:[379..387] designed)
        (NP-2 (-NONE-:[387..387] *))
        (S-PRP
          (NP-SBJ (-NONE-:[387..387] *))
          (VP (TO:[388..390] to)
            (VP (VB:[391..398] compare)
              (NP
                (NP (DT:[399..402] the) (NNS:[403..410] effects))
                (PP (IN:[411..413] of)
                  (NP
                    (NP (JJ:[414..423] exogenous)
                      (NML-1 (-NONE-:[423..423] *P*)))
                    (CC:[424..427] and)
                    (NP (JJ:[428..438] endogenous)
                      (NML-1 (NNS:[440..450] oestrogens)))))
                (PP (IN:[451..455] upon)
                  (NP
                    (NP (DT:[456..459] the) (NN:[460..470] expression))
                    (NP (IN:[471..473] of)
                      (NP (JJ:[474..481] steroid)
                        (NML
                          (NML (CD:[482..484] 17)
                               (NN:[485..502] alpha-hydroxylase))
                          (SYM:[502..503] /)
                          (NML
                            (NML (NN:[503..515] C17,20-lyase))
                            (NML (-LRB-:[517..518] -LRB-) (NN:[518..523] CYP17)
                                 (-RRB-:[523..524] -RRB-)))))))))
              (PP-LOC (IN:[525..527] in)
                (NP (DT:[528..531] the) (JJ:[532..540] immature)
                    (VBN:[541..558] hypophysectomized) (NN:[559..562] rat)
                    (NN:[563..568] ovary))))))))
    (.:[568..569] .)))

;sentence 5 Span:570..716
;C17,20-lyase activity was  measured ex vivo using [21-14C]progesterone, while
;serum concentrations of  androstenedione indicated in vivo activity.
;[570..582]:cyp450:"C17,20-lyase"
;[620..640]:substance:"[21-14C]progesterone"
;[673..688]:substance:"androstenedione"
(SENT
  (S
    (NP-SBJ-1 (NN:[570..582] C17,20-lyase) (NN:[583..591] activity))
    (VP (VBD:[592..595] was)
      (VP (VBN:[597..605] measured)
        (NP-1 (-NONE-:[605..605] *))
        (ADVP (FW:[606..608] ex) (FW:[609..613] vivo))
        (S-MNR
          (NP-SBJ (-NONE-:[613..613] *))
          (VP (VBG:[614..619] using)
            (NP (NN:[620..640] -LSB-21-14C-RSB-progesterone))))
        (,:[640..641] ,)
        (SBAR-ADV (IN:[642..647] while)
          (S
            (NP-SBJ
              (NP (NN:[648..653] serum) (NNS:[654..668] concentrations))
              (PP (IN:[669..671] of)
                (NP (NN:[673..688] androstenedione))))
            (VP (VBD:[689..698] indicated)
              (NP
                (ADJP (FW:[699..701] in) (FW:[702..706] vivo))
                (NN:[707..715] activity)))))))
    (.:[715..716] .)))

;sentence 6 Span:717..787
;Immunocytochemistry was used to  localize the enzyme within the ovary.
;[763..769]:substance:"enzyme"
(SENT
  (S
    (NP-SBJ-1 (NN:[717..736] Immunocytochemistry))
    (VP (VBD:[737..740] was)
      (VP (VBN:[741..745] used)
        (NP-1 (-NONE-:[745..745] *))
        (S-PRP
          (NP-SBJ (-NONE-:[745..745] *))
          (VP (TO:[746..748] to)
            (VP (VB:[750..758] localize)
              (NP (DT:[759..762] the) (NN:[763..769] enzyme))
              (PP-LOC (IN:[770..776] within)
                (NP (DT:[777..780] the) (NN:[781..786] ovary))))))))
    (.:[786..787] .)))

;sentence 7 Span:788..994
;Activity of CYP17 increased dramatically  and remained high in thecal and
;interstitial cells after injection of equine  chorionic gonadotrophin, even
;though serum oestradiol (OE2) levels exceeded 2  nmol/l.
;[800..805]:cyp450:"CYP17"
;[900..931]:substance:"equine  chorionic gonadotrophin"
;[951..961]:substance:"oestradiol"
;[963..966]:substance:"OE2"
;[984..985]:quantitative-value:"2"
;[987..993]:quantitative-units:"nmol/l"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[788..796] Activity))
      (PP (IN:[797..799] of)
        (NP (NN:[800..805] CYP17))))
    (VP
      (VP (VBD:[806..815] increased)
        (ADVP (RB:[816..828] dramatically)))
      (CC:[830..833] and)
      (VP (VBD:[834..842] remained)
        (ADJP-PRD (JJ:[843..847] high))
        (PP-LOC (IN:[848..850] in)
          (NP
            (NP (JJ:[851..857] thecal)
              (NML-1 (-NONE-:[857..857] *P*)))
            (CC:[858..861] and)
            (NP (JJ:[862..874] interstitial)
              (NML-1 (NNS:[875..880] cells)))))
        (PP-TMP (IN:[881..886] after)
          (NP
            (NP (NN:[887..896] injection))
            (PP (IN:[897..899] of)
              (NP (JJ:[900..906] equine) (JJ:[908..917] chorionic)
                  (NN:[918..931] gonadotrophin)))))
        (,:[931..932] ,)
        (SBAR-ADV
          (ADVP (RB:[933..937] even))
          (IN:[938..944] though)
          (S
            (NP-SBJ
              (NML
                (NML (NN:[945..950] serum) (NN:[951..961] oestradiol))
                (NML (-LRB-:[962..963] -LRB-) (NN:[963..966] OE2)
                     (-RRB-:[966..967] -RRB-)))
              (NNS:[968..974] levels))
            (VP (VBD:[975..983] exceeded)
              (NP
                (NP (CD:[984..985] 2) (NN:[987..991] nmol))
                (PP (SYM:[991..992] /)
                  (NP (NN:[992..993] l)))))))))
    (.:[993..994] .)))

;sentence 8 Span:995..1209
;Production of comparable serum levels by the use of Silastic capsules 
;containing OE2 greatly suppressed but did not stop, expression of the enzyme 
;induced by repeated doses of human chorionic gonadotrophin (hCG).
;[1077..1080]:substance:"OE2"
;[1136..1142]:substance:"enzyme"
;[1173..1202]:substance:"human chorionic gonadotrophin"
;[1204..1207]:substance:"hCG"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[995..1005] Production))
      (PP (IN:[1006..1008] of)
        (NP (JJ:[1009..1019] comparable) (NN:[1020..1025] serum)
            (NNS:[1026..1032] levels)))
      (PP (IN:[1033..1035] by)
        (NP
          (NP (DT:[1036..1039] the) (NN:[1040..1043] use))
          (PP (IN:[1044..1046] of)
            (NP
              (NP (NNP:[1047..1055] Silastic) (NNS:[1056..1064] capsules))
              (VP (VBG:[1066..1076] containing)
                (NP (NN:[1077..1080] OE2))))))))
    (VP
      (VP
        (ADVP (RB:[1081..1088] greatly))
        (VBD:[1089..1099] suppressed)
        (NP-1 (-NONE-:[1099..1099] *RNR*)))
      (CC:[1100..1103] but)
      (VP (VBD:[1104..1107] did) (RB:[1108..1111] not)
        (VP (VB:[1112..1116] stop)
          (NP-1 (-NONE-:[1116..1116] *RNR*))))
      (,:[1116..1117] ,)
      (NP-1
        (NP
          (NP (NN:[1118..1128] expression))
          (PP (IN:[1129..1131] of)
            (NP (DT:[1132..1135] the) (NN:[1136..1142] enzyme))))
        (VP (VBN:[1144..1151] induced)
          (NP (-NONE-:[1151..1151] *))
          (PP (IN:[1152..1154] by)
            (NP-LGS
              (NP (VBN:[1155..1163] repeated) (NNS:[1164..1169] doses))
              (PP (IN:[1170..1172] of)
                (NP
                  (NP (JJ:[1173..1178] human) (JJ:[1179..1188] chorionic)
                      (NN:[1189..1202] gonadotrophin))
                  (NP (-LRB-:[1203..1204] -LRB-) (NN:[1204..1207] hCG)
                      (-RRB-:[1207..1208] -RRB-)))))))))
    (.:[1208..1209] .)))

;sentence 9 Span:1210..1382
;Subcutaneous  implantation of Silastic capsules (1 cm) containing
;diethylstilboestrol (DES)  stimulated follicular growth and increased ovarian
;weight by 67%, 5 days later.
;[1259..1260]:quantitative-value:"1"
;[1261..1263]:quantitative-units:"cm"
;[1276..1295]:substance:"diethylstilboestrol"
;[1297..1300]:substance:"DES"
;[1364..1367]:quantitative-value:"67%"
;[1369..1370]:quantitative-value:"5"
;[1371..1375]:quantitative-units:"days"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1210..1222] Subcutaneous) (NN:[1224..1236] implantation))
      (PP (IN:[1237..1239] of)
        (NP
          (NP (NNP:[1240..1248] Silastic) (NNS:[1249..1257] capsules)
            (PRN (-LRB-:[1258..1259] -LRB-)
              (NP (CD:[1259..1260] 1) (NN:[1261..1263] cm))
              (-RRB-:[1263..1264] -RRB-)))
          (VP (VBG:[1265..1275] containing)
            (NP
              (NP (NN:[1276..1295] diethylstilboestrol))
              (NP (-LRB-:[1296..1297] -LRB-) (NN:[1297..1300] DES)
                  (-RRB-:[1300..1301] -RRB-)))))))
    (VP
      (VP (VBD:[1303..1313] stimulated)
        (NP (JJ:[1314..1324] follicular) (NN:[1325..1331] growth)))
      (CC:[1332..1335] and)
      (VP (VBD:[1336..1345] increased)
        (NP (JJ:[1346..1353] ovarian) (NN:[1354..1360] weight))
        (PP-EXT (IN:[1361..1363] by)
          (NP (CD:[1364..1366] 67) (NN:[1366..1367] %)))
        (,:[1367..1368] ,)
        (ADVP-TMP
          (NP-ADV (CD:[1369..1370] 5) (NNS:[1371..1375] days))
          (RB:[1376..1381] later))))
    (.:[1381..1382] .)))

;sentence 10 Span:1384..1564
;Injection of 50 IU hCG at various times after removal of the implant produced
; time-dependent changes in CYP17 activity and serum androstenedione levels,
;when  measured 30 h later.
;[1397..1399]:quantitative-value:"50"
;[1400..1402]:quantitative-units:"IU"
;[1403..1406]:substance:"hCG"
;[1489..1494]:cyp450:"CYP17"
;[1514..1529]:substance:"androstenedione"
;[1553..1555]:quantitative-value:"30"
;[1556..1557]:quantitative-units:"h"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1384..1393] Injection))
      (PP (IN:[1394..1396] of)
        (NP
          (NML (CD:[1397..1399] 50) (NN:[1400..1402] IU))
          (NN:[1403..1406] hCG)))
      (PP-TMP (IN:[1407..1409] at)
        (NP
          (NP (JJ:[1410..1417] various) (NNS:[1418..1423] times))
          (PP-TMP (IN:[1424..1429] after)
            (NP
              (NP (NN:[1430..1437] removal))
              (PP (IN:[1438..1440] of)
                (NP (DT:[1441..1444] the) (NN:[1445..1452] implant))))))))
    (VP (VBD:[1453..1461] produced)
      (NP
        (NP
          (ADJP (NN:[1463..1467] time) (HYPH:[1467..1468] -)
                (JJ:[1468..1477] dependent))
          (NNS:[1478..1485] changes))
        (PP (IN:[1486..1488] in)
          (NP
            (NP (NN:[1489..1494] CYP17) (NN:[1495..1503] activity))
            (CC:[1504..1507] and)
            (NP (NN:[1508..1513] serum) (NN:[1514..1529] androstenedione)
                (NNS:[1530..1536] levels)))))
      (,:[1536..1537] ,)
      (SBAR-ADV
        (WHADVP-1 (WRB:[1538..1542] when))
        (S
          (NP-SBJ-2 (-NONE-:[1542..1542] *))
          (VP (VBN:[1544..1552] measured)
            (NP-2 (-NONE-:[1552..1552] *))
            (ADVP-TMP
              (NP-ADV (CD:[1553..1555] 30) (NN:[1556..1557] h))
              (RB:[1558..1563] later))
            (ADVP-TMP-1 (-NONE-:[1563..1563] *T*))))))
    (.:[1563..1564] .)))

;sentence 11 Span:1565..1705
;Although the initial effect of removal of DES was an  increase in CYP17
;activity, delaying injection of hCG resulted in a reduced  response.
;[1607..1610]:substance:"DES"
;[1631..1636]:cyp450:"CYP17"
;[1669..1672]:substance:"hCG"
(SENT
  (S
    (SBAR-ADV (IN:[1565..1573] Although)
      (S
        (NP-SBJ
          (NP (DT:[1574..1577] the) (JJ:[1578..1585] initial)
              (NN:[1586..1592] effect))
          (PP (IN:[1593..1595] of)
            (NP
              (NP (NN:[1596..1603] removal))
              (PP (IN:[1604..1606] of)
                (NP (NN:[1607..1610] DES))))))
        (VP (VBD:[1611..1614] was)
          (NP-PRD
            (NP (DT:[1615..1617] an) (NN:[1619..1627] increase))
            (PP (IN:[1628..1630] in)
              (NP (NN:[1631..1636] CYP17) (NN:[1637..1645] activity)))))))
    (,:[1645..1646] ,)
    (S-NOM-SBJ
      (NP-SBJ (-NONE-:[1646..1646] *))
      (VP (VBG:[1647..1655] delaying)
        (NP
          (NP (NN:[1656..1665] injection))
          (PP (IN:[1666..1668] of)
            (NP (NN:[1669..1672] hCG))))))
    (VP (VBD:[1673..1681] resulted)
      (PP-CLR (IN:[1682..1684] in)
        (NP (DT:[1685..1686] a) (VBN:[1687..1694] reduced)
            (NN:[1696..1704] response))))
    (.:[1704..1705] .)))

;sentence 12 Span:1706..2126
;The results indicated that: (1) endogenous oestrogens do not inhibit  CYP17
;expression; (2) exogenous oestrogens only reduce the number of 
;thecal/interstitial cells expressing CYP17 when they are exposed to hCG; (3) 
;pretreatment with oestrogen removes the ovarian interstitial but not the
;thecal  cell expression of CYP17 in response to hCG; and (4) oestrogens can
;be  stimulatory for CYP17 expression in thecal cells.
;[1749..1759]:substance:"oestrogens"
;[1776..1781]:cyp450:"CYP17"
;[1808..1818]:substance:"oestrogens"
;[1883..1888]:cyp450:"CYP17"
;[1914..1917]:substance:"hCG"
;[1942..1951]:substance:"oestrogen"
;[2024..2029]:cyp450:"CYP17"
;[2045..2048]:substance:"hCG"
;[2058..2068]:substance:"oestrogens"
;[2093..2098]:cyp450:"CYP17"
(SENT
  (S
    (NP-SBJ (DT:[1706..1709] The) (NNS:[1710..1717] results))
    (VP (VBD:[1718..1727] indicated)
      (SBAR (IN:[1728..1732] that) (::[1732..1733] :)
        (S
          (S
            (LST (LS:[1734..1737] -LRB-1-RRB-))
            (NP-SBJ (JJ:[1738..1748] endogenous) (NNS:[1749..1759] oestrogens))
            (VP (VBP:[1760..1762] do) (RB:[1763..1766] not)
              (VP (VB:[1767..1774] inhibit)
                (NP (NN:[1776..1781] CYP17) (NN:[1782..1792] expression)))))
          (::[1792..1793] ;)
          (S
            (LST (LS:[1794..1797] -LRB-2-RRB-))
            (NP-SBJ (JJ:[1798..1807] exogenous) (NNS:[1808..1818] oestrogens))
            (ADVP (RB:[1819..1823] only))
            (VP (VBP:[1824..1830] reduce)
              (NP
                (NP (DT:[1831..1834] the) (NN:[1835..1841] number))
                (PP (IN:[1842..1844] of)
                  (NP
                    (NP
                      (NP (JJ:[1846..1852] thecal)
                        (NML-2 (-NONE-:[1852..1852] *P*)))
                      (SYM:[1852..1853] /)
                      (NP (JJ:[1853..1865] interstitial)
                        (NML-2 (NNS:[1866..1871] cells))))
                    (VP (VBG:[1872..1882] expressing)
                      (NP (NN:[1883..1888] CYP17))))))
              (SBAR-ADV
                (WHADVP-3 (WRB:[1889..1893] when))
                (S
                  (NP-SBJ-1 (PRP:[1894..1898] they))
                  (VP (VBP:[1899..1902] are)
                    (VP (VBN:[1903..1910] exposed)
                      (NP-1 (-NONE-:[1910..1910] *))
                      (PP-CLR (TO:[1911..1913] to)
                        (NP (NN:[1914..1917] hCG)))
                      (ADVP-TMP-3 (-NONE-:[1917..1917] *T*))))))))
          (::[1917..1918] ;)
          (S
            (LST (LS:[1919..1922] -LRB-3-RRB-))
            (NP-SBJ
              (NP (NN:[1924..1936] pretreatment))
              (PP (IN:[1937..1941] with)
                (NP (NN:[1942..1951] oestrogen))))
            (VP
              (VP (VBZ:[1952..1959] removes)
                (NP=6
                  (NP (DT:[1960..1963] the) (JJ:[1964..1971] ovarian)
                      (JJ:[1972..1984] interstitial)
                    (NML-4 (-NONE-:[1984..1984] *P*)))
                  (PP-5 (-NONE-:[1984..1984] *P*))))
              (CC:[1985..1988] but)
              (VP (RB:[1989..1992] not)
                (NP=6
                  (NP (DT:[1993..1996] the) (JJ:[1997..2003] thecal)
                    (NML-4 (NN:[2005..2009] cell) (NN:[2010..2020] expression)))
                  (PP-5 (IN:[2021..2023] of)
                    (NP (NN:[2024..2029] CYP17))))
                (PP (IN:[2030..2032] in)
                  (NP
                    (NP (NN:[2033..2041] response))
                    (PP (TO:[2042..2044] to)
                      (NP (NN:[2045..2048] hCG))))))))
          (::[2048..2049] ;) (CC:[2050..2053] and)
          (S
            (LST (LS:[2054..2057] -LRB-4-RRB-))
            (NP-SBJ (NNS:[2058..2068] oestrogens))
            (VP (MD:[2069..2072] can)
              (VP (VB:[2073..2075] be)
                (ADJP-PRD (JJ:[2077..2088] stimulatory)
                  (PP (IN:[2089..2092] for)
                    (NP (NN:[2093..2098] CYP17) (NN:[2099..2109] expression))))
                (PP-LOC (IN:[2110..2112] in)
                  (NP (JJ:[2113..2119] thecal) (NNS:[2120..2125] cells)))))))))
    (.:[2125..2126] .)))

;section 13 Span:2130..2174
;PMID: 7798031 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2130..2134] PMID) (::[2134..2135] :) (CD:[2136..2143] 7798031)
        (IN:[2144..2145] -LSB-) (NNP:[2145..2151] PubMed) (HYPH:[2152..2153] -)
        (JJ:[2154..2161] indexed) (IN:[2162..2165] for)
        (NNP:[2166..2174] MEDLINE-RSB-)))
